$ANIP
ANI Pharmaceuticals Inc

2014 Q3 Form 10-Q Financial Statement

#000114420414066225 Filed on November 10, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q1 2013 Q4
Revenue $17.39M $10.90M $10.53M
YoY Change 121.89% 95.95% 435.18%
Cost Of Revenue $3.061M $2.622M $2.910M
YoY Change 12.95% 8.89%
Gross Profit $14.33M $8.277M $7.620M
YoY Change 179.48% 162.43%
Gross Profit Margin 82.39% 75.94% 72.36%
Selling, General & Admin $4.057M $3.703M $3.200M
YoY Change 16.58% 60.3% -23.63%
% of Gross Profit 28.32% 44.74% 41.99%
Research & Development $883.0K $376.0K $520.0K
YoY Change 94.49% 25.33% -79.32%
% of Gross Profit 6.16% 4.54% 6.82%
Depreciation & Amortization $1.187M $703.0K $440.0K
YoY Change 210.73% 384.83% -8.33%
% of Gross Profit 8.29% 8.49% 5.77%
Operating Expenses $4.940M $4.079M $4.160M
YoY Change 25.57% 48.33% 65.43%
Operating Profit $8.199M $3.495M $3.460M
YoY Change 912.22% 767.25% -195.18%
Interest Expense $10.00K $0.00 $0.00
YoY Change -100.0%
% of Operating Profit 0.12% 0.0% 0.0%
Other Income/Expense, Net $82.00K $29.00K $30.00K
YoY Change -44.59% -158.0%
Pretax Income $8.291M $3.524M $3.490M
YoY Change 765.45% 1255.38% -84.31%
Income Tax $1.545M $165.0K $100.0K
% Of Pretax Income 18.63% 4.68% 2.87%
Net Earnings $6.746M $3.359M $3.430M
YoY Change 466.41% 1191.92% -84.56%
Net Earnings / Revenue 38.8% 30.82% 32.57%
Basic Earnings Per Share $0.59 $0.33
Diluted Earnings Per Share $0.59 $0.33 $359.2K
COMMON SHARES
Basic Shares Outstanding 11.24M shares 9.991M shares
Diluted Shares Outstanding 11.30M shares 10.00M shares

Balance Sheet

Concept 2014 Q3 2014 Q1 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.10M $51.40M $11.10M
YoY Change 222.02% 74.83%
Cash & Equivalents $35.05M $51.37M $11.11M
Short-Term Investments
Other Short-Term Assets $600.0K $600.0K $600.0K
YoY Change -79.31% -76.92% 100.0%
Inventory $7.346M $5.090M $3.518M
Prepaid Expenses $599.0K $566.0K $580.0K
Receivables $14.57M $10.91M $12.51M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $57.57M $67.94M $27.72M
YoY Change 120.6% 112.79% 223.56%
LONG-TERM ASSETS
Property, Plant & Equipment $5.046M $4.518M $4.537M
YoY Change 8.74% -7.03%
Goodwill $1.838M $1.838M $1.838M
YoY Change -0.02%
Intangibles $43.19M $22.36M $10.41M
YoY Change 303.16% 12145.88%
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $50.07M $28.72M $16.78M
YoY Change 191.27% 737.29% 223.89%
TOTAL ASSETS
Total Short-Term Assets $57.57M $67.94M $27.72M
Total Long-Term Assets $50.07M $28.72M $16.78M
Total Assets $107.6M $96.65M $44.50M
YoY Change 148.67% 173.37% 223.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.059M $2.660M $1.429M
YoY Change 46.58% 1230.0% -28.34%
Accrued Expenses $3.888M $1.013M $1.326M
YoY Change 190.54% 1.3% 43.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.145M $4.600M $3.538M
YoY Change 23.46% -50.54% -54.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.145M $4.600M $3.538M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $8.100M $4.600M $3.538M
YoY Change 22.73% -50.67% -66.6%
SHAREHOLDERS EQUITY
Retained Earnings -$40.73M -$45.11M -$48.47M
YoY Change -21.53% -81.75% 10.67%
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $68.00K $68.00K
YoY Change -100.0%
Treasury Stock Shares 0.000 shares 9.233K shares 9.233K shares
Shareholders Equity $99.49M $92.09M $40.96M
YoY Change
Total Liabilities & Shareholders Equity $107.6M $96.65M $44.50M
YoY Change 148.67% 173.03% 223.68%

Cashflow Statement

Concept 2014 Q3 2014 Q1 2013 Q4
OPERATING ACTIVITIES
Net Income $6.746M $3.359M $3.430M
YoY Change 466.41% 1191.92% -84.56%
Depreciation, Depletion And Amortization $1.187M $703.0K $440.0K
YoY Change 210.73% 384.83% -8.33%
Cash From Operating Activities $4.160M $5.179M -$2.860M
YoY Change -355.21% -2351.74% -113.01%
INVESTING ACTIVITIES
Capital Expenditures -$410.0K $118.0K -$30.00K
YoY Change 1266.67% 9.26% -112.5%
Acquisitions
YoY Change
Other Investing Activities -$22.11M -$12.52M $2.260M
YoY Change 22500.0%
Cash From Investing Activities -$22.53M -$12.64M $2.230M
YoY Change 75000.0% 11386.36% 792.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $50.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 460.0K $47.72M 810.0K
YoY Change 12729.03% -126.64%
NET CHANGE
Cash From Operating Activities 4.160M $5.179M -2.860M
Cash From Investing Activities -22.53M -$12.64M 2.230M
Cash From Financing Activities 460.0K $47.72M 810.0K
Net Change In Cash -17.91M $40.27M 180.0K
YoY Change 978.92% 10724.73% -99.06%
FREE CASH FLOW
Cash From Operating Activities $4.160M $5.179M -$2.860M
Capital Expenditures -$410.0K $118.0K -$30.00K
Free Cash Flow $4.570M $5.061M -$2.830M
YoY Change -385.62% -1597.34% -113.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1480000 USD
CY2013Q4 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
766000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
3518000 USD
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
580000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
27716000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12513000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11105000 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4537000 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
140221000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40730000 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
99492000 USD
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3633000 USD
us-gaap Depreciation
Depreciation
400000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3538000 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
68000 USD
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10409000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
1838000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1429000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1326000 USD
CY2013Q4 anip Returned Goods Reserve
ReturnedGoodsReserve
736000 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
47000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, allowance for doubtful accounts, accruals for chargebacks, returns and other allowances, allowance for inventory obsolescence, allowances for contingencies and litigation, fair value of long-lived assets, deferred taxes and valuation allowance, and the depreciable and amortizable lives of long-lived assets. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3059000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35050000 USD
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14570000 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
7346000 USD
CY2014Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
599000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
57565000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5046000 USD
CY2014Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
43188000 USD
CY2014Q3 us-gaap Goodwill
Goodwill
1838000 USD
CY2014Q3 us-gaap Assets
Assets
107637000 USD
CY2013Q4 us-gaap Assets
Assets
44500000 USD
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3888000 USD
CY2014Q3 anip Returned Goods Reserve
ReturnedGoodsReserve
1178000 USD
CY2014Q3 us-gaap Deferred Revenue
DeferredRevenue
20000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8145000 USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89501000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48472000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
40962000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44500000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Overview</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> ANI Pharmaceuticals, Inc. and subsidiary, ANIP Acquisition Company (together, the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;us&#8221;) is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Our targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. We have two pharmaceutical manufacturing facilities located in Baudette, Minnesota, which are capable of producing oral solid dose products, as well as liquids and topicals, narcotics, and potent products that must be manufactured in a fully-contained environment. Our strategy is to continue to use these manufacturing assets to develop, produce, and distribute niche generic pharmaceutical products.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> On June 19, 2013, pursuant to a merger agreement dated as of April 12, 2013, ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. ("ANIP") became a wholly-owned subsidiary of BioSante Pharmaceuticals, Inc. (&#8220;BioSante&#8221;) in an all-stock, tax-free reorganization (the "Merger"). The Merger was accounted for as a reverse acquisition, pursuant to which ANIP was considered the acquiring entity for accounting purposes. BioSante was renamed ANI Pharmaceuticals, Inc. We now operate under the leadership of the ANIP management team and our board of directors is comprised of two former BioSante directors and five former ANIP directors. As such, ANIP's historical results of operations replace BioSante's historical results of operations for all periods prior to the Merger. The results of operations of both companies are included in our consolidated financial statements for all periods after completion of the Merger.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q4 us-gaap Inventory Gross
InventoryGross
3560000 USD
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
42000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107637000 USD
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
19695000 USD
CY2013Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
7836000 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-3179000 USD
CY2013Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
1692000 USD
CY2013Q2 us-gaap Share Price
SharePrice
1.22
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
8100000 USD
CY2013Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
5104000 USD
CY2014Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
0 shares
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
9233 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1666667 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1666667 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
7088000 USD
CY2013Q2 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
29795000 USD
CY2013Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
18198000 USD
CY2013Q2 anip Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
2260000 USD
CY2013Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
10900000 USD
CY2013Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
79000 USD
CY2013Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Assets Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent
0 USD
CY2013Q2 us-gaap Goodwill
Goodwill
1838000 USD
CY2013Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
33275000 USD
CY2013Q2 anip Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Severance
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedSeverance
2965000 USD
CY2013Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
515000 USD
CY2013Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
3480000 USD
CY2014Q3 anip Business Combination Purchase Price Allocation Deferred Tax Assets Net
BusinessCombinationPurchasePriceAllocationDeferredTaxAssetsNet
0 USD
CY2013Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
29795000 USD
CY2013Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
500000 USD
CY2014Q3 anip Business Combination Deferred Tax Assets Established Gross
BusinessCombinationDeferredTaxAssetsEstablishedGross
9600000 USD
CY2014Q3 anip Business Combination Deferred Tax Liabilities Established Gross
BusinessCombinationDeferredTaxLiabilitiesEstablishedGross
3900000 USD
CY2014Q3 anip Business Combination Deferred Tax Asset Liability Valuation Allowance Established
BusinessCombinationDeferredTaxAssetLiabilityValuationAllowanceEstablished
-5700000 USD
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
6200000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3700000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
700000 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900000 shares
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
700000 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
469000 shares
CY2014Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
4455000 USD
CY2014Q3 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
671000 USD
CY2014Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
391000 USD
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
162000 USD
CY2014Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1945000 USD
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1152000 USD
CY2014Q3 us-gaap Inventory Gross
InventoryGross
7462000 USD
CY2014Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
116000 USD
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8679000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7734000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3197000 USD
us-gaap Depreciation
Depreciation
436000 USD
CY2013Q3 us-gaap Depreciation
Depreciation
134000 USD
CY2014Q3 us-gaap Depreciation
Depreciation
153000 USD
us-gaap Revenues
Revenues
19550000 USD
us-gaap Revenues
Revenues
34933000 USD
CY2013Q3 us-gaap Revenues
Revenues
7836000 USD
CY2014Q3 us-gaap Revenues
Revenues
17387000 USD
us-gaap Cost Of Revenue
CostOfRevenue
7290000 USD
us-gaap Cost Of Revenue
CostOfRevenue
7800000 USD
CY2013Q3 us-gaap Cost Of Revenue
CostOfRevenue
2710000 USD
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
3061000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1188000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2110000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
454000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
883000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12961000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13193000 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3480000 USD
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4057000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
673000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2596000 USD
CY2013Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
382000 USD
CY2014Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1187000 USD
us-gaap Costs And Expenses
CostsAndExpenses
22112000 USD
us-gaap Costs And Expenses
CostsAndExpenses
25699000 USD
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
7026000 USD
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
9188000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2562000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
9234000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
810000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
8199000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-467000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
13000 USD
CY2013Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
CY2014Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-336000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
148000 USD
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
82000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3365000 USD
CY2013Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
11000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9319000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
958000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8291000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-83000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1577000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-83000 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1545000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3132000 USD
us-gaap Net Income Loss
NetIncomeLoss
7742000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
1191000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
6746000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3282000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
6746000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4974000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2013Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
us-gaap Undistributed Earnings
UndistributedEarnings
-8256000 USD
us-gaap Undistributed Earnings
UndistributedEarnings
7742000 USD
CY2013Q3 us-gaap Undistributed Earnings
UndistributedEarnings
1041000 USD
CY2014Q3 us-gaap Undistributed Earnings
UndistributedEarnings
6746000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.71
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.70
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.59
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3577000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10824000 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9480000 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11235000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3577000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10865000 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9480000 shares
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11302000 shares
CY2014Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
45999000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11060000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2811000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
651000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1122000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4485000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4485000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
4485000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
4485000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
24126000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
43188000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2200000 USD
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000 USD
CY2014Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000 USD
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
1800000 USD
CY2013Q4 anip Intangible Asset Purchase Agreement Quantity Acquired
IntangibleAssetPurchaseAgreementQuantityAcquired
31 pure
CY2013Q4 anip Intangible Asset Purchase Type Of Products
IntangibleAssetPurchaseTypeOfProducts
generic drug products
CY2013Q4 anip Intangible Asset Purchase Agreement Amount
IntangibleAssetPurchaseAgreementAmount
12500000 USD
CY2014Q1 anip Intangible Asset Purchase Agreement Payment
IntangibleAssetPurchaseAgreementPayment
8500000 USD
CY2014Q1 anip Intangible Asset Purchase Agreement Payment
IntangibleAssetPurchaseAgreementPayment
4000000 USD
CY2013Q4 anip Intangible Asset Purchase Agreement Number Of Immediate Release Products
IntangibleAssetPurchaseAgreementNumberOfImmediateReleaseProducts
20 pure
CY2013Q3 anip Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Subject To Shareholder Approval Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingSubjectToShareholderApprovalNumber
325000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
36000 shares
CY2014Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5000 shares
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2500000 USD
CY2013Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3000 USD
CY2014Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
600000 USD
anip Share Based Compensation Catch Up
ShareBasedCompensationCatchUp
1300000 USD
CY2014Q3 anip Share Based Compensation Catch Up
ShareBasedCompensationCatchUp
1300000 USD
us-gaap Restricted Stock Expense
RestrictedStockExpense
0 USD
us-gaap Restricted Stock Expense
RestrictedStockExpense
218000 USD
CY2013Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
0 USD
CY2014Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
97000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
64000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4000 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.00
CY2014Q1 anip Stock Issued During Period Due To Warrant Exercise Number
StockIssuedDuringPeriodDueToWarrantExerciseNumber
20000 shares
anip Class Of Warrant Or Right Number Of Securities Called By Warrants That Expired During Period Number
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsThatExpiredDuringPeriodNumber
198000 shares
CY2014Q3 anip Class Of Warrant Or Right Number Of Securities Called By Warrants That Expired During Period Number
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsThatExpiredDuringPeriodNumber
67000 shares
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1600000 shares
CY2014Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
31.00
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50000000 USD
CY2014Q1 us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
46700000 USD
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3300000 USD
CY2014Q1 anip Stock Issued During Period Shares New Issues Due To Exercise Of Option To Purchase Additional Shares
StockIssuedDuringPeriodSharesNewIssuesDueToExerciseOfOptionToPurchaseAdditionalShares
200000 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.169 pure
CY2014Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.186 pure
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
223000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
26000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
53000 USD
CY2014Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
17000 USD
anip Loss Contingency Settlement Amount Between Insurance Carrier And Plaintiff Value
LossContingencySettlementAmountBetweenInsuranceCarrierAndPlaintiffValue
60000 USD
CY2014Q3 anip Contingent Consideration Classified As Liability Fair Value Disclosure
ContingentConsiderationClassifiedAsLiabilityFairValueDisclosure
0 USD
CY2013Q4 anip Contingent Consideration Classified As Liability Fair Value Disclosure
ContingentConsiderationClassifiedAsLiabilityFairValueDisclosure
0 USD
us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.15 pure
us-gaap Share Based Compensation
ShareBasedCompensation
3000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2719000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-217000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
anip Non Cash Compensation Relating To Business Combination
NonCashCompensationRelatingToBusinessCombination
4418000 USD
anip Non Cash Compensation Relating To Business Combination
NonCashCompensationRelatingToBusinessCombination
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4083000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2057000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3296000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
188000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
19000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
93000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
630000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-382000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2977000 USD
us-gaap Indefinitelived Intangible Assets Acquired
IndefinitelivedIntangibleAssetsAcquired
0 USD
us-gaap Indefinitelived Intangible Assets Acquired
IndefinitelivedIntangibleAssetsAcquired
-34634000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2380000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
11292000 USD
us-gaap Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
18198000 USD
us-gaap Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
0 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0 USD
anip Cancellation Of Redeemable Convertible Preferred And Common Stock Value
CancellationOfRedeemableConvertiblePreferredAndCommonStockValue
53726000 USD
anip Cancellation Of Redeemable Convertible Preferred And Common Stock Value
CancellationOfRedeemableConvertiblePreferredAndCommonStockValue
0 USD
anip Acquired Non Cash Net Assets
AcquiredNonCashNetAssets
11597000 USD
anip Acquired Non Cash Net Assets
AcquiredNonCashNetAssets
0 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
4974000 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 USD
dei Document Type
DocumentType
10-Q
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
162000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
782000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
18036000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-35416000 USD
us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
0 USD
us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
46680000 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-4065000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
433000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
777000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
180000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
0 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
432000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4498000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48069000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10919000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23945000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10930000 USD
us-gaap Interest Paid
InterestPaid
250000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
137000 USD
us-gaap Stock Issued1
StockIssued1
40034000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
ANI PHARMACEUTICALS INC
dei Entity Central Index Key
EntityCentralIndexKey
0001023024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
ANIP
us-gaap Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax
DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
-150000 USD
us-gaap Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax
DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
0 USD
CY2013Q3 us-gaap Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax
DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
-150000 USD
CY2014Q3 us-gaap Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax
DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
0 USD
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.31
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.71
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.11
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.59
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.04
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2013Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.02
CY2014Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.31
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.70
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.11
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.59
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.04
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2013Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.02
CY2014Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-239000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2619000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11292000 USD
anip Contingent Payment For Asset Purchase
ContingentPaymentForAssetPurchase
0 USD
anip Contingent Payment For Asset Purchase
ContingentPaymentForAssetPurchase
1000000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8256000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
7645000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1022000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6661000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
150000 USD
CY2013Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
150000 USD
anip Gain On Discontinued Operations Allocated To Common Shares Basic
GainOnDiscontinuedOperationsAllocatedToCommonSharesBasic
147000 USD
CY2013Q3 anip Gain On Discontinued Operations Allocated To Common Shares Basic
GainOnDiscontinuedOperationsAllocatedToCommonSharesBasic
147000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8256000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
7646000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1022000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
6662000 USD
anip Gain On Discontinued Operations Allocated To Common Shares Diluted
GainOnDiscontinuedOperationsAllocatedToCommonSharesDiluted
147000 USD
CY2013Q3 anip Gain On Discontinued Operations Allocated To Common Shares Diluted
GainOnDiscontinuedOperationsAllocatedToCommonSharesDiluted
147000 USD

Files In Submission

Name View Source Status
0001144204-14-066225-index-headers.html Edgar Link pending
0001144204-14-066225-index.html Edgar Link pending
0001144204-14-066225.txt Edgar Link pending
0001144204-14-066225-xbrl.zip Edgar Link pending
anip-20140930.xml Edgar Link completed
anip-20140930.xsd Edgar Link pending
anip-20140930_cal.xml Edgar Link unprocessable
anip-20140930_def.xml Edgar Link unprocessable
anip-20140930_lab.xml Edgar Link unprocessable
anip-20140930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v390961_10q.htm Edgar Link pending
v390961_ex10-1.htm Edgar Link pending
v390961_ex10-2.htm Edgar Link pending
v390961_ex31-1.htm Edgar Link pending
v390961_ex31-2.htm Edgar Link pending
v390961_ex32-1.htm Edgar Link pending